This review summarizes how specific lncRNAs drive therapeutic resistance through diverse mechanisms such as acting as competitive endogenous RNAs (ceRNAs) to sponge tumor-suppressive microRNAs, and by modulating key signaling pathways like PI3K/Akt and Wnt/β-catenin. This evidence concerns the gene AKT1 and neoplasm.